All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the EHA2021 Virtual Congress, the ALL Hub spoke with Sabina Chiaretti, Sapienza University of Rome, Rome, IT. We asked, How can we improve dasatinib results in newly diagnosed Philadelphia chromosome-positive (Ph+) ALL?
D-ALBA trial: How can we improve dasatinib results in newly diagnosed Ph+ ALL?
In this video, Chiaretti discusses the feasibility of improving the results of a chemotherapy-free regimen with dasatinib for patients with newly diagnosed Ph+ ALL.
Too much of a good thing? An in vitro study with dual Src/ABL kinase inhibitor and blinatumomab suggests some combination treatments for Ph+ ALL may not work well together
The most common cytogenic abnormality in adult patients with acute...
Updated results from the D-ALBA trial of dasatinib plus blinatumomab in newly diagnosed adult Ph+ ALL
The outcomes of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) are historically poor; however, they have...
Subscribe to get the best content related to ALL delivered to your inbox